Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Marina Elena Cazzaniga, Martina Dester, Valentina Arcangeli et al.|The Breast|2017

Cited by 23